Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.

ESMO open·2026

Same author

Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study.

Frontiers in immunology·2026

Same author

Quest for Cooper Pair Transfer in Heavy-Ion Reactions: The ^{206}Pb+^{118}Sn Case.

Physical review letters·2024

Same author

First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia.

Annals of hematology·2022

Same author

Differential disease phenotypes and progression in relapsing-remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinics.

BMC neurology·2021

Same author

Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2021

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Cetuximab in colon cancer.

F Giuliani¹, G Colucci

¹Department of Medical Oncology, National Cancer Institute, Bari, Italy.

The International Journal of Biological Markers

|May 24, 2007

Summary

New biologic agents like cetuximab offer enhanced treatment for metastatic colorectal cancer. Further research is needed to optimize its use with chemotherapy and patient selection.

Area of Science:

Oncology
Medical Biochemistry
Pharmacology

Background:

Metastatic colorectal cancer treatment has advanced with oxaliplatin and irinotecan.
Biological agents, such as cetuximab, are being explored to improve chemotherapy efficacy.
Cetuximab targets the epidermal growth factor receptor (EGFR).

Purpose of the Study:

To review the current role and potential of cetuximab in metastatic colorectal cancer treatment.
To evaluate cetuximab's efficacy as a single agent and in combination therapies.
To identify areas for future research regarding cetuximab's application.

Main Methods:

Review of clinical practice and published trial data.
Analysis of cetuximab's activity in pretreated patients.

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jul 14, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Assessment of ongoing phase II and pending phase III trials.

Main Results:

Cetuximab shows activity in pretreated metastatic colorectal cancer patients, alone or with irinotecan.
Cetuximab plus irinotecan is approved for EGFR-expressing mCRC post-irinotecan failure.
Phase II trials of cetuximab plus chemotherapy show high response rates and promising survival data.

Conclusions:

Cetuximab represents a valuable addition to metastatic colorectal cancer therapy, particularly after irinotecan failure.
Its role in first-line therapy and adjuvant/neoadjuvant settings requires further investigation.
Defining patient selection criteria for cetuximab therapy is crucial for optimizing outcomes.